Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

First…I want to thank everyone who took the time to offer comments on my post. Even the mistaken observations were of value.

Second…JJ, I am in complete agreement with your points that Elite is no longer singularly focused on the opioids business. Indeed, it is a good thing, given the socio-political-legal issues with opioids. But it does not mean there is no value in their portfolio of approved pain drugs or their ADF platform. Rather, they remain part of how Elite would be valued. Kind of like unused manufacturing plants; they still count as corporate value.

Third...I want to offer corrections and additions to my post yesterday:

To begin with, in the post I mistakenly said SunGen5 and, of course, it should be SunGen2. Sorry about that.

Also, it has been said that Elite has to share all its new revenues equally with its partners. That is incorrect. As was made obvious on the CC, Elite takes manufacturing fees for all its drugs off the top! Then, as is common among partnerships (and a little research makes clear), the developers (Elite & SunGen) get a larger percentage than the commercializer (Lannett/Glenmark); with the actual amount a matter of agreement and those specifics are not something outsiders would know.

Okay, a question for the board…On the CC, Nasrat mentioned uplisting onto the Nasdaq and the timeline seems to be traveling further into the horizon. What do you make of the ever-moving target date? (And, saying he has been lying is not a viable option!)